Contribution of genetic background and clinical D:A:D risk score to chronic kidney disease in Swiss HIV-positive persons with normal baseline estimated glomerular filtration rate.

Détails

ID Serval
serval:BIB_CEFAD592E5CD
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Contribution of genetic background and clinical D:A:D risk score to chronic kidney disease in Swiss HIV-positive persons with normal baseline estimated glomerular filtration rate.
Périodique
Clinical infectious diseases
Auteur(s)
Dietrich L.G., Barceló C., Thorball C.W., Ryom L., Burkhalter F., Hasse B., Furrer H., Weisser M., Steffen A., Bernasconi E., Cavassini M., de Seigneux S., Csajka C., Fellay J., Ledergerber B., Tarr P.E.
Collaborateur(s)
Swiss HIV CohortS Study
ISSN
1537-6591 (Electronic)
ISSN-L
1058-4838
Statut éditorial
In Press
Peer-reviewed
Oui
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: aheadofprint
Résumé
In HIV, the relative contribution of genetic background, clinical risk factors, and antiretrovirals to chronic kidney disease (CKD) is unknown.
We applied a case-control design and performed genome-wide genotyping in white Swiss HIV Cohort participants with normal baseline estimated glomerular filtration rate (eGFR >90 mL/min/1.73 m2). Uni- and multivariable CKD odds ratios (OR) were calculated based on the D:A:D score that summarizes clinical CKD risk factors and a polygenic risk score that summarizes genetic information from 86613 single nucleotide polymorphisms..
We included 743 cases (79% male; median age, 42 years; baseline eGFR 106 mL/min/1.73 m2) with confirmed eGFR drop to <60 mL/min/1.73 m2 (n=144) or ≥25% eGFR drop to <90 mL/min/1.73 m2 (n=599), and 322 controls (eGFR drop <15%; 81% male; median age, 39 years, baseline eGFR 107 mL/min/1.73 m2). Polygenic risk score and D:A:D score contributed to CKD. In multivariable analysis, CKD ORs were 2.13 (95% confidence interval, 1.55-2.97) in participants in the 4th (most unfavorable) vs. 1st (most favorable) genetic score quartile; 1.94 (1.37-2.65) in the 4th vs. 1st D:A:D score quartile; and 2.98 (2.02-4.66), 1.70 (1.29-2.29), and 1.83 (1.45-2.40), per 5-years exposure to atazanavir/ritonavir, lopinavir/ritonavir, and tenofovir disoproxil fumarate, respectively. Participants in the 1st genetic score quartile had no increased CKD risk, even if they were in the 4th D:A:D score quartile.
Genetic score increased CKD risk similar to clinical D:A:D score and potentially nephrotoxic antiretrovirals. Irrespective of D:A:D score, individuals with the most favorable genetic background may be protected against CKD.
Mots-clé
kidney disease, HIV infection, S, antiretroviral therapy, chronic, clinical risk factors, genetics
Pubmed
Création de la notice
15/04/2019 18:04
Dernière modification de la notice
21/08/2019 5:33
Données d'usage